Argyrophilic Grain Disease: Demographics, Clinical, and Neuropathological Features From a Large Autopsy Study
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Argyrophilic grain disease (AGD) is a frequent late-onset, 4-repeat tauopathy reported in Caucasians with high educational attainment. Little is known about AGD in non-Caucasians or in those with low educational attainment. We describe AGD demographics, clinical, and neuropathological features in a multiethnic cohort of 983 subjects ≥50 years of age from São Paulo, Brazil. Clinical data were collected through semistructured interviews with an informant and included in the Informant Questionnaire on Cognitive Decline in the Elderly, the Clinical Dementia Rating, and the Neuropsychiatric Inventory. Neuropathologic assessment relied on internationally accepted criteria. AGD was frequent (15.2%) and was the only neuropathological diagnosis in 8.9% of all cases (mean, 78.9 ± 9.4 years); it rarely occurred as an isolated neuropathological finding. AGD was associated with older age, lower socioeconomic status (SES), and appetite disorders. This is the first study of demographic, clinical, and neuropathological aspects of AGD in different ethnicities and subjects from all socioeconomic strata. The results suggest that prospective studies of AGD patients include levels of hormones related to appetite control as possible antemortem markers. Moreover, understanding the mechanisms behind higher susceptibility to AGD of low SES subjects may disclose novel environmental risk factors for AGD and other neurodegenerative diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Phases of Aβ-deposition in the human brain and its relevance for the development of AD
Thal, D. R., Rüb, U., Orantes, M., & Braak, H. (2002) · Neurology · doi:10.1212/wnl.58.12.1791 · Cited by 3,490 · cited 1×
“AD-type pathology was scored using the Braak and Braak staging system, the Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) criteria and the Thal et al phase system for b-amyloid plaques (55).”
MethodMontine, T. J., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., Mirra, S. S., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0910-3 · Cited by 2,894 · cited 1×
“A neuropathological diagnosis of AD was granted to individuals showing, at least, intermediate AD neuropathologic changes (52).”
MethodMackenzie, I. R. A., Neumann, M., Bigio, E. H., Cairns, N. J., Alafuzoff, I., Kril, J., Kovacs, G. G., Ghetti, B., Halliday, G., Holm, I. E., et al. (2010) · Acta Neuropathologica · doi:10.1007/s00401-009-0612-2 · Cited by 1,012 · cited 1×
“(44) Internationally accepted neuropathological criteria and guidelines were used for diagnosing and staging.(51-53) AD-type pathology was scored using the Braak and Braak staging system, the Consortium to Establish a Registry for AD (CERAD) criteria and the Thal et al.”
MethodNeuropathology of Cognitively Normal Elderly
Knopman, D. S., Parisi, J. E., Salviati, A., Floriach-Robert, M., Boeve, B. F., Ivnik, R. J., Smith, G. E., Dickson, D. W., Johnson, K. A., Petersen, L. E., et al. (2003) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/62.11.1087 · Cited by 674
Alzheimer neuropathologic alterations in aged cognitively normal subjects
Davis, D. G., Schmitt, F. A., Wekstein, D. R., & Markesbery, W. R. (1999) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199904000-00008 · Cited by 516 · cited 1×
“Davis et al found AGD in 23% of a total sample of 59 older cognitively normal subjects (37).”
BackgroundEvans, D. A., Hebert, L. E., Beckett, L. A., Scherr, P. A., Albert, M. S., Chown, M. J., Pilgrim, D. M., & Taylor, J. O. (1997) · Archives of Neurology · doi:10.1001/archneur.1997.00550230066019 · Cited by 435 · cited 1×
“14 risk of developing neurodegenerative conditions in late life.(59-62).”
BackgroundBraak, H., & Braak, E. (1987) · Neuroscience Letters · doi:10.1016/0304-3940(87)90204-7 · Cited by 236
Hypothalamic and other connections with dorsal CA2 area of the mouse hippocampus
Cui, Z., Gerfen, C. R., & Young, W. S. (2013) · Journal of Comparative Neurology · doi:10.1002/cne.23263 · Cited by 214 · cited 1×
“(66) Moreover, the hypothalamus connects to the hippocampal CA2 sector in mice, including the paraventricular nucleus that participates in appetite regulation.(67-69) CA2 is extremely vulnerable to AGD pathology, although it is resistant to other tauopathies, including AD.”
BackgroundBrazilian Aging Brain Study Group, Grinberg, L. T., de Lucena Ferretti, R. E., Farfel, J. M., Leite, R., Pasqualucci, C. A., Rosemberg, S., Nitrini, R., Saldiva, P. H. N., & Jacob Filho, W. (2007) · Cell and Tissue Banking · doi:10.1007/s10561-006-9022-z · Cited by 169 · cited 2×
“The BBBABSG receives brain donations from individuals who die in the metropolitan area of S~ao Paulo (11 million inhabitants) and receive an autopsy in the S~ao Paulo Autopsy Service (45).”
BackgroundSelf-citationLein, E. S., Callaway, E. M., Albright, T. D., & Gage, F. H. (2005) · Journal of Comparative Neurology · doi:10.1002/cne.20426 · Cited by 158
Neuropathology of mild cognitive impairment
Saito, Y., & Murayama, S. (2007) · Neuropathology · doi:10.1111/j.1440-1789.2007.00806.x · Cited by 92
Tolnay, M., Sergeant, N., Ghestem, A., Chalbot, S., de Vos, R. A., Jansen Steur, E. N., Probst, A., & Delacourte, A. (2002) · Acta Neuropathologica · doi:10.1007/s00401-002-0591-z · Cited by 89 · cited 1×
“Only recently, studies showing distinct AGD characteristics such lack of acetylated tau settled AGD as an independent entity.(6, 14-21) AGD features three principal neuropathological hallmarks, all containing phospho-tau: 1) argyrophilic grains (AGs), 2) oligodendrocytic coiled”
BackgroundThal, D. R., Schultz, C., Botez, G., Del Tredici, K., Mrak, R. E., Griffin, W. S. T., Wiestler, O. D., Braak, H., & Ghebremedhin, E. (2005) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2005.00635.x · Cited by 69 · cited 1×
“The lack of distinctive antemortem clinical features of AGD and the extensive overlap between AGD and other dementing conditions represent considerable challenges to the understanding of the impact of AGD on cognitive decline (19, 20, 65, 66).”
BackgroundFerrer, I., Barrachina, M., Tolnay, M., Rey, M. J., Vidal, N., Carmona, M., Blanco, R., & Puig, B. (2003) · Brain Pathology · doi:10.1111/j.1750-3639.2003.tb00007.x · Cited by 60
Cited by
Molecular characterization of selectively vulnerable neurons in Alzheimer’s disease
Leng, K., Li, E., Eser, R., Piergies, A., Sit, R., Tan, M., Neff, N., Li, S. H., Rodriguez, R. D., Suemoto, C. K., et al. (2021) · Nature Neuroscience · doi:10.1038/s41593-020-00764-7 · Cited by 485
Self-citationTauopathies: new perspectives and challenges
Zhang, Y., Wu, K.-M., Yang, L., Dong, Q., & Yu, J.-T. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00533-z · Cited by 323
Comorbid neuropathological diagnoses in early versus late-onset Alzheimer's disease
Spina, S., La Joie, R., Petersen, C., Nolan, A. L., Cuevas, D., Cosme, C., Hepker, M., Hwang, J.-H., Miller, Z. A., Huang, E. J., et al. (2021) · Brain · doi:10.1093/brain/awab099 · Cited by 278
“While the significance of amygdala-predominant LBD in determining the AD Alzheimer’s disease clinical phenotype is likely limited,47–49 recent observations have proposed the existence of distinctive biochemical characteristics of the amygdala-predominant a-synuclein aggregates, which may be more informative regarding…”
ResultInfluentialSelf-citationTen Years of Tau-Targeted Immunotherapy: The Path Walked and the Roads Ahead
Novak, P., Kontsekova, E., Zilka, N., & Novak, M. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00798 · Cited by 87
Tau at the interface between neurodegeneration and neuroinflammation
Didonna, A. (2020) · Genes & Immunity · doi:10.1038/s41435-020-00113-5 · Cited by 82
Metadata
- Authors
- Rodriguez, R. D., Suemoto, C. K., Molina, M., Nascimento, C. F., Leite, R. E. P., de Lucena Ferretti-Rebustini, R. E., Farfel, J. M., Heinsen, H., Nitrini, R., Ueda, K., Pasqualucci, C. A., Jacob-Filho, W., Yaffe, K., & Grinberg, L. T.
- Venue
- Journal of Neuropathology & Experimental Neurology
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-06-09
- Volume
- 75
- Issue
- 7
- Pages
- 628-635
- ISSN
- 0022-3069 (ISSN-L)
- 1554-6578
- OpenAlex
- W2411933725
- Cited by
- 95
- References
- 15
- FWCI
- 5.93
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.